Brief: Cassava Sciences Completes Interim Safety Review Of Oral Simufilam On-Going Phase 3 Trials

Filana Therapeutics

25/03/2024 13:28

March 25 (Reuters) - Cassava Sciences Inc  SAVA.O :
    * CASSAVA SCIENCES ANNOUNCES COMPLETION OF AN INTERIM SAFETY
REVIEW OF ORAL SIMUFILAM ON-GOING PHASE 3 TRIALS
    * CASSAVA SCIENCES INC - FINAL CLINICAL SAFETY DATA FOR
SIMUFILAM
ARE EXPECTED AT CONCLUSION OF PHASE 3 PROGRAM
    * CASSAVA SCIENCES INC - DSMB RECOMMENDED BOTH PHASE 3
TRIALS
CONTINUE AS PLANNED, WITHOUT MODIFICATION
    * CASSAVA SCIENCES INC - TOP-LINE RESULTS FOR 52-WEEK PHASE
3
TRIAL ARE CURRENTLY EXPECTED APPROXIMATELY YEAR-END 2024
    * CASSAVA SCIENCES INC - TOP-LINE RESULTS FOR 76-WEEK PHASE
3
TRIAL ARE CURRENTLY EXPECTED APPROXIMATELY MID-YEAR 2025

Source text for Eikon:  ID:nGNX44YW69 
Further company coverage:  SAVA.O 

 ((Reuters.Briefs@thomsonreuters.com;))